Inflammatory vaginitis in four B-cell suppressed women with Multiple Sclerosis.

Autor: Levine L; Department of Neurology, Columbia University Irving Medical Center, USA., Son J; Department of Neurology, Columbia University Irving Medical Center, USA., Yu A; Baptist Health South Florida, Marcus Neuroscience Institute, USA., Wesley S; Department of Neurology, Columbia University Irving Medical Center, USA., De Jager PL; Department of Neurology, Columbia University Irving Medical Center, USA., Moynihan E; Department of Neurology, Columbia University Irving Medical Center, USA., Farber RS; Department of Neurology, Columbia University Irving Medical Center, USA., Rosser M; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, USA., Haque H; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, USA., Riley CS; Department of Neurology, Columbia University Irving Medical Center, USA. Electronic address: csr53@columbia.edu.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Feb; Vol. 82, pp. 105387. Date of Electronic Publication: 2023 Dec 16.
DOI: 10.1016/j.msard.2023.105387
Abstrakt: B-cell depleting therapies are effective in multiple sclerosis (MS) and are widely used (Hauser et al., 2017). Inflammatory vaginitis (IV), characterized by unexplained vaginal symptoms including mucopurulent discharge, pain, irritation, and dyspareunia, has been reported in one MS patient on ocrelizumab (Filikci and Jensen, 2022), and to be present in 3.5 % of women on rituximab for autoimmune diseases (Yockey et al., 2021). We report here four cases of IV in B cell depleted women with MS. B-cell reconstitution was temporally associated with improvement of IV symptoms. Further investigation and vigilance for this potential treatment emergent adverse event affecting sexual and reproductive health of women with MS is needed.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Claire S. Riley reports a relationship with TG Therapeutics Inc that includes: consulting or advisory. Claire S. Riley reports a relationship with Novartis Pharmaceuticals Corporation that includes: consulting or advisory and travel reimbursement. Claire S. Riley reports a relationship with Genentech that includes: consulting or advisory. Claire S. Riley reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Claire S. Riley reports a relationship with EMD Serono Inc that includes: consulting or advisory. Claire S. Riley reports a relationship with Biogen that includes: consulting or advisory. Amy Yu reports a relationship with Genentech that includes: consulting or advisory. Rebecca Straus Farber reports a relationship with Genentech that includes: consulting or advisory. Rebecca Straus Farber reports a relationship with Novartis that includes: funding grants. Rebecca Straus Farber reports a relationship with Biogen that includes: funding grants.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: